logo
Plus   Neg
Share
Email

Skechers Q3 Results Beat Wall Street, Outlook Strong; Stock Up 8%

Shares of Skechers USA Inc. (SKX) gained 8% in extended session Thursday after the footwear company's third quarter earnings and revenues trumped Wall Street estimates. The company also issued a strong outlook for the fourth quarter.

Skechers' third-quarter profit dropped $90.7 million or $0.58 per share from $92.3 million or $0.59 per share last year. On average, 12 analysts polled by Thomson Reuters estimate earnings of $0.51 per share for the quarter.

Sales for the quarter grew 7.5% to $1.18 billion from $1.09 billion last year. Analysts' had a consensus revenue estimate of $1.22 billion for the quarter.

Sales growth reflects an 11.8 percent increase in the company's international wholesale business, and a 10.6 percent increase in company-owned global retail business.

Third-quarter comparable same store sales in company-owned retail stores worldwide increased 1.9 percent, including an increase of 3.0 percent in the United States offset by a decrease of 0.8 percent in its international stores.

Gross margins slightly increased as higher domestic margins from improved retail pricing and product mix were partially offset by the impact of negative foreign currency exchange rates.

Looking forward to fourth quarter, Skechers expects sales of $1.100 billion to $1.125 billion and earnings of $0.20 to $0.25 per share. Analysts currently estimate revenues of $1.08 billion and earnings of $0.18 per share.

SKX closed Thursday's trading at $26.12, down $0.57 or 2.14%, on the NYSE. The stock, however, gained $2.12 or 8.12% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Palantir Technologies Inc., the Silicon Valley big data analytics company that has handled U.S. government's certain sensitive projects, said it has confidentially filed documents with the Securities and Exchange Commission to go public. In a statement, the company said the proposed public listing of its Class A common stock is expected to take place after the SEC completes its review process.
RELATED NEWS
Follow RTT